Success Story: Fast-Track NIW Success! Senior Research Technologist Approved in 25 Days Thanks to Our Expert Filing and Premium Processing
Client’s Testimonial:
“Thank you so much!!!! I can't believe how quickly this got approved. Can't thank you enough.”
On March 11th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Research Technologist in the Field of Liver Disease (Approval Notice).
General Field: Liver Disease
Position at the Time of Case Filing: Senior Research Technologist
Country of Origin: Sri Lanka
State of Residence at the Time of Filing: Minnesota
Approval Notice Date: March 11th, 2025
Processing Time: 25 days (Premium Processing Requested)
Case Summary:
We are proud to announce the approval of an I-140 NIW (National Interest Waiver) petition for a promising early-career researcher whose work is transforming the fight against liver cancer. This approval marks a significant milestone in the client’s efforts to continue pioneering research on improving outcomes for patients with intrahepatic cholangiocarcinoma.
Our client's approach holds promise in unveiling new molecular mechanisms for combating one of the most aggressive forms of liver cancer. Her work is designed to enhance treatment options and offer hope to patients who currently face limited clinical outcomes and survival prospects.
The client is currently employed in a research-focused role where she is actively designing and conducting both in vitro and in vivo studies. Her ongoing research contributes directly to the development of targeted virotherapies and is disseminated through peer-reviewed publications and scientific presentations, solidifying her place at the forefront of translational liver cancer research.
To support the petition under the EB-2 NIW category, her record included:
● 2 peer-reviewed journal articles and 5 scientific abstracts,
● A total of 31 citations to date, demonstrating growing academic influence,
● Research published in top-tier journals, including a paper ranked among the top 10% most-cited in Molecular Biology & Genetics for its publication year,
● Funding from the National Institutes of Health (NIH), affirming the national relevance of her scientific contributions.
Her published work has provided new insight into molecular processes such as SAMe-sensitive LARP1 phosphorylation in liver cancer progression and AKAP12 phosphorylation in liver fibrosis, and has been cited by researchers exploring everything from hepatocellular carcinoma signaling to fibrosis regulation in liver disease.To further substantiate her qualifications and impact, four expert letters of recommendation (3 independent letters and 1 dependent letter) were submitted, including one from an independent source.
“All of this shows that [Client] is a highly prominent researcher in liver disease who is mitigating the progression of liver diseases and contributing to the development of more effective therapeutic strategies. As [Client’s] findings play a critical role in guiding the development of more efficient treatments, it is clear that they are of great value to the field and that she is an irreplaceable presence in the research sphere.”
We congratulate this client on her well-deserved NIW approval. With the guidance and support of NAILG, we are excited to witness the future advancements she will make in cancer treatment and public health outcomes in the United States.